Merkel Cell Carcinoma Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Neoadjuvant Cemiplimab in Stage I-II Merkel Cell Carcinoma: Safety and Biomarker Analysis
Condition: Merkel Cell Carcinoma Intervention: Drug: Cemiplimab-Rwlc Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Regeneron Pharmaceuticals; Sanofi-Synthelabo Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 23, 2021 Category: Research Source Type: clinical trials
